2018-11-12T13:07:00-06:00 2017-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2017-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 2062853500 2018-11-12 1 3019519090 75.103.231.202 2018-11-12 14:06:56 ES P 4FA38BE9C690C82C721A5060F87FC7588CB81F81 92DED79A3FD2BE8CA1FF310A7D004DEBEF0EEB01 2017 2019-02-21 02:37:17Z OLIVIA D POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 33220750 0 X WWW.PATH.ORG X 2006 WA SEE PART III, LINE 1. 7 2 0 0 0 0 4727165 6592045 0 0 1239778 504329 23560 12542 5990503 7108916 29855678 30367803 0 0 0 0 0 0 0 12217095 13366543 42072773 43734346 -36082270 -36625430 107465507 66391789 15803401 14042965 91662106 52348824 X THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-INCOME COUNTRIES BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST.FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT.PVS WORKS WITH PARTNERS TO DEVELOP NEW VACCINES BY PROVIDING FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE COUNTRIES. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN DEVELOPING COUNTRIES. 0 0 43734346 30367803 PVS WORKS TO PREVENT DEATH AND DISEASE CAUSED BY DIARRHEA, PNEUMONIA, INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS, AND POLIO AMONG CHILDREN AROUND THE WORLD. WE ACCELERATE THE DEVELOPMENT OF SAFE, EFFICACIOUS, AND AFFORDABLE VACCINES IN PARTNERSHIP WITH PUBLIC AND PRIVATE GROUPS. IN 2017, PVS CONTINUED OUR FIGHT AGAINST DIARRHEAL DISEASES, THE SECOND LEADING CAUSE OF DEATH AMONG CHILDREN IN LOW-INCOME COUNTRIES. TO COMBAT ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, WE CONTINUED CLINICAL DEVELOPMENT OF A NONREPLICATING ROTAVIRUS VACCINE CANDIDATE. THIS TYPE OF ROTAVIRUS VACCINE WOULD BE ADMINISTERED AS AN INTRAMUSCULAR INJECTION AND COULD POTENTIALLY OVERCOME THE LOWER EFFICACY LEVELS SEEN IN LOW-RESOURCE SETTINGS FOR ORAL, LIVE, ATTENUATED VACCINES. WE ALSO COMPLETED A STUDY WITH SERUM INSTITUTE OF INDIA PVT. LTD. (SIIPL) OF A ROTAVIRUS VACCINE ABLE TO REMAIN STABLE AND POTENT DURING EXTENDED PERIODS WITHOUT REFRIGERATION, ENABLING WIDER USE IN REMOTE COMMUNITIES. IN SEPTEMBER 2017, THE GOVERNMENT OF INDIA ORDERED SIIPL'S VACCINE, ROTASIIL, FOR USE IN THE COUNTRY'S UNIVERSAL IMMUNIZATION PROGRAM. IN ADDITION, ROTAVAC, ANOTHER INDIAN-MADE VACCINE DEVELOPED WITH PATH SUPPORT, ADVANCED TOWARD WORLD HEALTH ORGANIZATION PREQUALIFICATION. WE CONTINUED TO CONDUCT EARLY-STAGE CLINICAL TRIALS OF VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, LEADING CAUSES OF BACTERIAL DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. WE ALSO ADVANCED DEVELOPMENT OF LOW-COST VACCINE CANDIDATES TO PROTECT CHILDREN AGAINST PNEUMOCOCCAL BACTERIA, THE TOP CAUSE OF SEVERE CHILDHOOD PNEUMONIA. IN 2017, WE BEGAN A PHASE 3 STUDY IN THE GAMBIA TO EVALUATE A PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10) CANDIDATE DESIGNED TO BE AFFORDABLE AND TO PROVIDE PROTECTION AGAINST TEN BACTERIAL SEROTYPES THAT CAUSE MOST CASES OF INVASIVE PNEUMOCOCCAL DISEASE IN AFRICA AND ASIA. IN KENYA, WE STUDIED A VACCINE CANDIDATE WITH THE POTENTIAL TO PROVIDE LOW-COST, BROAD PROTECTION ACROSS MANY SEROTYPES. 43734346 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS CHAIR AND PRESIDENT 1.00 39.00 X X 0 641522 65784 PENNY HEATON VICE CHAIR 1.00 0.00 X X 0 0 0 OLIVIA D POLIUS TREASURER 1.00 39.00 X X 0 311327 53104 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 334058 41018 AMIE E BATSON DIRECTOR 1.00 39.00 X 0 312831 27395 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 368007 67708 CHRIS KARP DIRECTOR 1.00 0.00 X 0 0 0 0 1967745 255009 0 0 1 0 0 6592045 6592045 646343 646343 25969820 26111834 -142014 -142014 -142014 OTHER REIMBURSEMENTS 900099 12542 12542 12542 7108916 0 0 516871 23543484 23543484 6824319 6824319 6246 6246 1664 1664 40554 40554 381903 381903 4433 4433 236297 236297 34168 34168 2500 2500 1193427 1193427 88630 88630 45152 45152 37525 37525 SUBCONTRACTORS 10885797 10885797 LAB SUPPLIES 235358 235358 STORAGE 85469 85469 EQUIPMENT R&M 79561 79561 7859 7859 43734346 43734346 0 0 32558748 21866566 202886 0 70 56033 261010 236662 42765 24348 74661038 44444842 107465507 66391789 15803401 14042965 15803401 14042965 X 18107 8544 91643999 52340280 91662106 52348824 107465507 66391789 X -36625430 86322 -2774174 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 43734346 0 1 43734346 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 261010 236662 24348 24348 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 136360 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 232554 EUROPE 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 573248 EUROPE 0 0 GRANTMAKING 4535641 NORTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 15192 SOUTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 7589 SOUTH ASIA 0 5 PROGRAM SERVICES ESSENTIAL MEDICINE 1062217 SOUTH ASIA 0 0 GRANTMAKING 1422862 SUB-SAHARAN AFRICA 0 1 PROGRAM SERVICES ESSENTIAL MEDICINE 755150 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 633262 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 1699 0 5 0 1 0 6 7985663 1390111 9375774 SOUTH ASIA ESSENTIAL MEDICINE 318406 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 5161 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 908727 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 180469 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 97929 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 463425 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 242865 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 20619 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 1402243 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 52085 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 74902 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 2235000 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 265851 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 59816 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 200000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 50000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 26118 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 142190 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 225221 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE -247717 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE -32963 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE -12796 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 146769 CHECK/WIRE 19 4 1 0 0 0 0 0 PART I, LINE 2: PVS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PVS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 1 ADVANCED BIOSCIENCE LABORATORIES INC 9800 MEDICAL CENTER DRIVE BUILDING D ROCKVILLE MD 20850 621242262 N/A 1148163 PRODUCT DEVELOPMENT BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 340000 PRODUCT DEVELOPMENT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER ACCOUNTING DEPARTMENT MLC 4900 3333 BURNE CINCINNATI OH 45229 310833936 501(C)(3) 882368 PRODUCT DEVELOPMENT FAMILY HEALTH INTERNATIONAL 360 FHI 360 HEADQUARTERS 359 BLACKWELL ST SUITE 200 DURHAM NC 27701 237413005 501(C)(3) 31230 PRODUCT DEVELOPMENT FOOD & DRUG ADMINISTRATION 10903 NEW HAMPSHIRE AVENUE SILVER SPRING MD 20993 530196965 GOV 80000 PRODUCT DEVELOPMENT HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE 4301 JONES BRIDGE ROAD ROOM G074 BETHESDA MD 20814 521317896 501(C)(3) 497310 PRODUCT DEVELOPMENT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1428 MADISON AVENUE NEW YORK NY 10029 136171197 501(C)(3) 224000 PRODUCT DEVELOPMENT IMMPORT THERAPEUTICS INC 1 TECHNOLOGY DRIVE SUITE E309 IRVINE CA 92618 050543092 N/A 234526 PRODUCT DEVELOPMENT INFECTIOUS DISEASE RESEARCH INSTITUTE 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 911608978 501(C)(3) 1343203 PRODUCT DEVELOPMENT JHU BLOOMBERG SCHOOL OF PUBLIC HEALTH 615 N WOLFE STREET BALTIMORE MD 21205 131687001 501(C)(3) 225584 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY OFFICE OF RESEARCH ADMIN 615 N WOLFE STREET W1100 BALTIMORE MD 21205 131687001 501(C)(3) 326104 PRODUCT DEVELOPMENT KANSAS STATE UNIVERSITY 2 FAIRCHILD HALL DEPT OF GRAIN SCIENCE INDUSTRY MANHATTAN KS 66506 480771751 501(C)(3) 169560 PRODUCT DEVELOPMENT LANKENAU INSTITUTE FOR MEDICAL RESEARCH 100 E LANCASTER AVE WYNNEWOOD PA 190963450 232175659 501(C)(3) 81668 PRODUCT DEVELOPMENT TULANE EDUCATIONAL FUND 1430 TULANE AVENUE TB-32 NEW ORLEANS LA 701122632 720423889 501(C)(3) 58060 PRODUCT DEVELOPMENT UNITED STATES NAVAL MEDICAL RESEARCH CENTER 503 ROBERT GRANT AVE SILVER SPRING MD 209107500 470100048 GOV 858868 PRODUCT DEVELOPMENT UNIVERSITY OF KANSAS CENTER FOR RESEARCH INC 2385 IRVING HILL ROAD LAWRENCE KS 66045 480680117 501(C)(3) 18000 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 501(C)(3) 265356 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE CENTER FOR VACCINE DEVELOPMENT 685 WEST BALTIMORE STREET BALTIMORE MD 21201 526002033 501(C)(3) 873058 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH 503 ROBERT GRANT AVENUE SILVER SPRING MD 209107500 520664528 GOV 590550 PRODUCT DEVELOPMENT BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 352940111 636001138 501(C)(3) -16482 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 15312358 PRODUCT DEVELOPMENT 19 2 PART I, LINE 2: PVS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PVS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS CHAIR AND PRESIDENT 0 486134 0 147638 0 7750 0 32200 0 33584 0 707306 0 0 OLIVIA D POLIUS TREASURER 0 309227 0 0 0 2100 0 32400 0 20704 0 364431 0 0 DANIEL LASTER SECRETARY 0 332258 0 0 0 1800 0 32400 0 8618 0 375076 0 0 AMIE E BATSON DIRECTOR 0 301024 0 0 0 11807 0 26579 0 816 0 340226 0 0 DAVID C KASLOW DIRECTOR 0 358097 0 0 0 9910 0 32400 0 35308 0 435715 0 0 PART I, LINE 3 PVS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG & FREEDMAN, CPAS), USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PVS'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PVS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PVS BOARD MEMBERS AND OFFICERS MUST ANNUALLY COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM. PVS DOES NOT HAVE EMPLOYEES. PVS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF INTERNAL REVENUE CODE SECTION 509(A)(3) AND CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF AT HIGHER THAN A DESIGNATED LEVEL MUST ANNUALLY COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM. ALL PVS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION C, LINE 19 PVS'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. FORM 990, PART XI, LINE 9: FROM TIME TO TIME, UNSPENT AWARD FUNDS (OR UNUSED OBLIGATIONS) MAY BE RETURNED TO A FUNDER FOR A VARIETY OF REASONS INCLUDING, BUT NOT LIMITED TO, EARLY TERMINATION OF A PROJECT BY A FUNDER OR A REDUCTION IN FUNDS REQUIRED TO ACCOMPLISH A PROJECT'S SCOPE OF WORK. -2,774,174. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH DRUG SOLUTIONS 600 CALIFORNIA STREET SUITE 14-001 SAN FRANCISCO CA 94108 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND RUE DE VAREMBE 7 GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0